Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

Documenti analoghi

• Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
  di: Zabriskie, Matthew S., et al.
  Pubblicazione: (2015)
• Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
  di: Qiang, Wang, et al.
  Pubblicazione: (2017)
• BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia
  di: Antelope, Orlando, et al.
  Pubblicazione: (2019)
• Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
  di: Snead, Jennifer L., et al.
  Pubblicazione: (2009)
• The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
  di: O'Hare, Thomas, et al.
  Pubblicazione: (2011)